Newsletter sign up

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.

ADC University Our services

ADC Review
is made possible by:

2nd Annual Cancer Immunotherapy Summit

Published on 13th June

Vonlanthen Group of Companies, a fast-growing multinational company that is an experienced provider of conferences, summits, exhibitions, and training programs, producing events within 6 different industries,will be hosting the 2nd Annual Cancer Immunotherapy Summit on September 21st – 22nd, 2017 in Vienna, Austria.

Following the success of the 1st Annual Cancer Immunotherapy Summit and the continued viability of immunotherapy as a cancer treatment we bring the second instalment in the series.

Immunotherapy upholds as being one of the most successful approaches to cancer treatment since the discovery of chemotherapy. To pursue this option as a feasible form of treatment, there needs to be an adequate forum for experts to share their findings and technologies. The purpose of this Summit is to bring experts, scientists, and researchers together to discuss the latest research, advancements, and developments in immunotherapy to continue the successful development of this as a form of cancer treatment.

Dr. Saso Cemerski, Principal Scientist, Merck Sharp & Dohme Ltd, USA and chairman of the event, states the importance of this topic and the need for this event: ‘Cancer treatment has moved into a new era with therapies that target the immune system showing unprecedented success in previously difficult to treat indications. While targeting negative T-cell regulators, PD-1 and CTLA-4, drove much of the initial success it also created an immediate need to identify new targets on T-cells and other immune cells present in the tumour microenvironment. Next generation targets, next generation combinations, new technologies and platforms are all critical factors that will allow improvement of the initial clinical success immuno-oncology as a field has brought to patients.

As we continue to work bringing forward from discovery into clinical development drugs that demonstrate strong preclinical proof of concept, we also continue to learn through reverse translation how to best define patient population that will respond to new therapies, how to design best biomarker plans and ultimately, design the best protocols for clinical trials. The 2nd Annual Cancer Immunotherapy Summit will surely be a great opportunity to share some of the latest research and development in the field and stimulate additional progress in the future.’

We are assembling innovators from oncology, drug development, antibody engineering, cell and gene therapy, and others for a two-day summit to espouse the latest developments in Cancer Immunotherapy research. Through a detailed outlay of the current state and future progressions in this form of treatment, attendees will be exposed to new findings. This will include:

  • The success of antibodies in therapeutics and engineering
  • The potential of the next generation immune checkpoint pathways
  • Revolutionary cancer treatments with personalized cancer vaccines
  • Reinforcing anti-tumour immunity
  • Managing unique immune-mediated adverse reactions and toxicity effects in treatment therapies
  • Progressions in genetic engineering techniques and progressions in preclinical and clinical Cancer Immunotherapy
  • Car T-cell therapy as an influence on cancer treatment
  • Regulatory aspects of the EU and the rest of the world for immunotherapy

We are excited to be hosting this critical event, as the outcome will have a lasting impact on cancer treatment therapies. Join us for what will be an engaging and insightful opportunity for those concerned with Cancer Immunotherapy development. Registration is available till September 19, 2017.


Print Friendly, PDF & Email


Facebook share Twitter share Linkedin share Google Plus share

Featured Event

Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...

Skip to toolbar